Ficlatuzumab: Completed Phase II enrollment

In June, Aveo completed enrollment of 188 patients in the Phase II portion of an open-label, Asian Phase Ib/II trial comparing 20 mg/kg IV ficlatuzumab every 2 weeks in 28-day cycles plus once-daily 250 mg oral Iressa gefitinib vs. Iressa alone. Aveo previously reported data from the dose-escalating Phase Ib portion in 12 evaluable patients that showed that the combination led to 5 partial responses and 4 cases of stable disease (see BioCentury, June 6). ...